Trends in Pharma – Report Bundle (4 Reports)

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

Trends in Pharma Industry Overview

‘The pharmaceutical sector is witnessing a massive revamp. It has been conventionally slow in the adoption of technology and is now undergoing rapid changes due to the development of several technologies as well as innovations. From modern cancer research facilities to gene treatment centers, the novel association between the human mind and technology has become a self-evolving matter. Post-COVID, equipped with cutting-edge technology, the prominent pharma industry tends to invest increasingly in inter-organizational collaborations to boost a favorable environment for innovation across it. ’

As a part of this bundle, you will gain access to in-depth insights available in the following reports:

To get a snapshot of the trends in pharma bundle, download a free report sample

Report 1: The State of the Biopharmaceutical Industry

COVID-19 has been a wake-up call for the pharmaceutical industry to innovate, rethink its operations, and adopt new ways of working. To harness relationships with customers, regulators, and investors, it is understood that digitalization is going to be an inseparable part of the industry’s transformation roadmaps. The healthcare industry made quick decisions and fast investments to ensure business continuity, dispelling the stereotype of being risk-averse. AI, followed by big data, will continue to trend as an integral part of the future of pharmaceutical research and healthcare service delivery. With the increasing volume and complexity of data being generated by the sector, the need to analyze information will continue to pose challenges that can be best addressed by AI. As pressures to manage sustainability risks are intensifying on a global scale, the pharmaceutical industry will need to act on this trend as well. As a part of post-COVID-19 recovery agendas, many businesses have already started incorporating greener processes in R&D, supply chain, waste, and resource management to address ESG issues.

For more insights on the state of the biopharmaceutical industry, download a free report sample

Report 2: Thematic Research: Neuroimmunology Drug Development

Key industry trends in neuroimmunology drug development include the application of similar mechanisms of action (MOA) across numerous indications as well as the development of mAbs targeting pathogenic neural proteins in Alzheimer’s disease (AD) and Parkinson’s disease (PD), among others. Across the 8MM, the top 20 neuroimmunology products, by sales, are forecast to increase from $20.1 billion in 2020. Ocrevus is expected to be the highest-earning product. In the neuroimmunology space, Roche and its subsidiaries, Chugai and Genentech, market Ocrevus for MS and Enspryng for NMOSD. The company also has nine pipeline products in clinical development.

For more insights on neuroimmunology drug development, download a free report sample

Report 3: Thematic Research: Microbiome-Targeting Therapeutics in Immunology

Small and mid-sized biotech companies currently dominate the pipeline for microbiome-targeting therapeutics. Players from large pharma companies, such as Takeda and J&J have made it a priority to partner with smaller biotech companies and academy labs to further the development of microbiome-targeting therapeutics in immunology. No microbiome targeting therapy has received marketing approval yet. Although regulatory agencies are adapting preexisting guidance for other types of drugs to microbiome-targeting therapies, specific guidance for this new class of drugs will likely be established over the next decade. Developers must anticipate regulatory agency concerns as best they can, but without specified guidance, there may be some delays in the approval process.

For more insights on microbiome-targeting therapeutics in immunology, download a free report sample

Report 4: Thematic Research: Gene Therapy in Oncology

There are currently just 3 gene therapies marketed for oncology indications in the eight major pharmaceutical markets (8 MM) (the US, France, Germany, Italy, Spain, the UK, Japan, and China). The market for gene therapies, especially those using viral vectors, is expected to be slowed down by the high cost of therapies, which may limit their accessibility. There are currently three marketed gene therapies for cancer indications and 81 in vivo gene therapies in development across the 8MM. Viral vector gene therapies have a high list price when they come to market. This restricts patient access, especially in countries where the healthcare systems are less developed.

For more insights on gene therapy in oncology, download a free report sample

The State of the Biopharmaceutical Industry 2022


Thematic Research: Neuroimmunology Drug Development

Thematic Research: Microbiome-Targeting Therapeutics in Immunology

  • 4D Pharma

  • Rebiotix

  • NuBiyota

  • KoBioLabs

  • AOBiome

  • Seres Therapeutics

  • MatriSys

  • Evelo Biosciences

  • Siolta Therapeutics

  • Enterome

Thematic Research: Gene Therapy in Oncology

  • Amgen

  • SiBiono

  • Sunway Biotech

  • Candel

  • CG Oncology

  • Checkmate

  • Daiichi Sankyo

  • Ferring

  • Geron

  • FKD

Table of Contents

The State of the Biopharmaceutical Industry 2022

Study Design

Key Findings

Emerging Industry Trends

Emerging Regulatory and Macroeconomic Trends

Emerging Technologies

Industry Growth Prospects

Watch Outs

Summary of Key Findings


Contact Us

Thematic Research: Neuroimmunology Drug Development

Executive Summary

Neuroimmunology Overview


Value chain

Marketed Products

Pipeline products

Clinical Trials

Market Analysis

Opportunities, Challenges, and Unmet Needs



Contact us

Thematic Research: Microbiome-Targeting Therapeutics in Immunology

Executive Summary



Value chain

Current Therapies

Pipeline Drugs

Market Analysis

Regulatory and Market Access

Opportunities, Challenges, and Unmet Needs



Contact us

Thematic Research: Gene Therapy in Oncology

Executive Summary

Gene Therapy Overview


Value chain

Current Therapies

Marketed Products

Pipeline Products

Market Analysis and Deals

Regulatory and Market Access

Opportunities, Challenges, and Unmet Needs



Contact us

Frequently asked questions

Trends in Pharma – Report Bundle (4 Reports) standard reports
Currency USD
$2,950 $3,980 (26% off)

Can be used by individual purchaser only

$5,950 $7,980 (25% off)

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

Trends in Pharma – Report Bundle (4 Reports) was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Trends in Pharma – Report Bundle (4 Reports) in real time.

  • Access a live Trends in Pharma – Report Bundle (4 Reports) dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.